Arno Therapeutics, Inc. is a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. The company is headquartered in Flemington, New Jersey. The company went IPO on 2008-06-11. The firm's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The firm is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Follow-Up Questions
Quel est le ratio P/E de Arno Therapeutics Inc (ARNI) ?
Le ratio P/E de Arno Therapeutics Inc est de 0
Qui est le CEO de Arno Therapeutics Inc ?
Dr. Alexander Zukiwski est le Chief Executive Officer de Arno Therapeutics Inc, il a rejoint l'entreprise depuis 2011.
Quelle est la performance du prix de l'action ARNI ?
Le prix actuel de ARNI est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Arno Therapeutics Inc ?
Arno Therapeutics Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Arno Therapeutics Inc ?
La capitalisation boursière actuelle de Arno Therapeutics Inc est de $0
